 The study aimed to improve the performance of CLE-C3A-derived Amps HT16 and HT47 by applying different sequence modifications, resulting in the generation of seven new peptides. WRK30 was identified as a novel antimicrobial peptide with enhanced potency against S. aureus and MRSA, and lower cytotoxicity to eukaryotic cells, suggesting its potential for wider use in an in vivo setting. This article was offered by Denise Meinberger, Marco G. Drexelius, Joshua Grabeck, and others.